Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oregon Health and Science University
With
National Institute of Neurological Disorders and Stroke (NINDS)
Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as PD progresses. Attention deficits in PD patients with dementia strongly predict the impairment of their daily living activities.
Previous studies have shown that atomoxetine improves PD executive dysfunction and rivastigmine improves attention deficits in PD patients with dementia without worsening the motor symptoms.
The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention and quality of life in PD patients without disabling cognitive impairment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of Parkinson's disease
Respond to levodopa therapy
You may not be if
Dementia
Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD
Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization
Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders);
Currently using any of the study drugs;
Colorblindness
Clareo Health | Cognitive Decline in Non-demented PD
